3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Withdrawn
1
Recruiting
1
Sponsor Class
INDUSTRY
5
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
2
Genitourinary
2
Thoracic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Prostatic Neoplasms
4399
Urinary Bladder Neoplasms
1078
Carcinoma, Renal Cell
1041
Kidney Neoplasms
567
Breast Neoplasms
453
Neoplasms
403
Carcinoma, Transitional Cell
299
Neoplasm Metastasis
250
Lung Neoplasms
242
Testicular Neoplasms
202
Melanoma
195
Colorectal Neoplasms
193
Ovarian Neoplasms
163
Carcinoma, Non-Small-Cell Lung
150
Sarcoma
135
Non-Muscle Invasive Bladder Neoplasms
135
Pancreatic Neoplasms
124
Colonic Neoplasms
121
Head and Neck Neoplasms
116
Uterine Cervical Neoplasms
115
Wilms Tumor
108
Recurrence
106
Motor Activity
100
Stomach Neoplasms
89
Urologic Neoplasms
88
Neuroblastoma
88
Disease
85
Multiple Myeloma
83
Carcinoma, Hepatocellular
79
Adenocarcinoma
79
Interventions
infigratinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Acrocephalosyndactylia
×
Genitourinary
×
Clear all
NCT07292168
2026-01-21
TAGNOT
Kidney Cancer Research Bureau
Phase 1/2
Recruiting
58 enrolled
NCT04972253
2022-08-10
(BLASST)-3
Dana-Farber Cancer Institute
Phase 1
Withdrawn